1. Home
  2. NTGR vs CTNM Comparison

NTGR vs CTNM Comparison

Compare NTGR & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NETGEAR Inc.

NTGR

NETGEAR Inc.

HOLD

Current Price

$24.15

Market Cap

672.3M

Sector

Utilities

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$15.93

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTGR
CTNM
Founded
1996
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
672.3M
550.7M
IPO Year
2000
2024

Fundamental Metrics

Financial Performance
Metric
NTGR
CTNM
Price
$24.15
$15.93
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$39.00
$19.00
AVG Volume (30 Days)
352.9K
249.7K
Earning Date
04-29-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.64
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.00
$5.71
52 Week High
$36.86
$16.91

Technical Indicators

Market Signals
Indicator
NTGR
CTNM
Relative Strength Index (RSI) 51.79 60.62
Support Level $20.36 $11.73
Resistance Level $25.33 $16.91
Average True Range (ATR) 1.09 1.07
MACD 0.06 0.09
Stochastic Oscillator 54.85 85.02

Price Performance

Historical Comparison
NTGR
CTNM

About NTGR NETGEAR Inc.

Netgear Inc provider of networking technologies for businesses, homes, and service providers. It delivers a wide range of intelligent solutions designed to unleash the full potential of connectivity. The group has two segments: Enterprise and Consumer which offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of organizations of all sizes. The Home Networking and Mobile offers connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, and Others. It conduct business across three geographic territories: Americas; Europe, Middle East and Africa; and Asia Pacific.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: